Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Deals Signed With UK’s NHS Pilot Scheme
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
You may also be interested in...
Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.
The industry-backed investment fund to combat antimicrobial resistance hopes to be operational by end of year and begin assessing programs to invest in during the first quarter of 2021.
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.